Read time: 2 minutes.

Here we present the final video in our three-part series about how patients and researchers can work together to develop clinical trials.  

Read time: 2 minutes.  

We are pleased to continue our three-part series about how patients and researchers can work together to develop clinical trials.  

Read time: 3 minutes.

Throughout 2024 we published blogs sharing scientific meeting recaps, educational content, personal stories, treatment news, and so much more. Below are the most popular articles we published in 2024. 

LUNGevity had a tremendous year supporting impactful research in 2024. In addition to our existing portfolio of ongoing research grants, we issued several new research awards in 2024. All of these awards are in strategic areas of research that are likely to move the dial for people living with lung cancer today and those who will be diagnosed in the future.  

Below are more details about the research projects we recently announced funding for. 

Read time: 5 minutes.

This year marks 20 years since researchers made a key discovery that changed the face of lung cancer research and treatment. 

By uncovering EGFR’s role in lung cancer, researchers developed a new class of drugs—targeted therapies—designed to target specific mutations in lung cancer cells while leaving healthy cells unharmed. 

As we’ve welcomed this era of precision medicine, we’ve also benefited from other treatment progress in lung cancer—including the development of effective immunotherapies.  

This is the second blog in our series of updates from the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference, held in Barcelona from September 13-17. This update focuses on small cell lung cancer (SCLC), which is seen in 15% of people diagnosed with lung cancer.  

You can read the other update blogs from these fall science meetings: 

Lung cancer screening and early detection were major topics of discussion at the World Conference on Lung Cancer (WCLC), held in San Diego from September 7-10, and the European Society for Medical Oncology (ESMO) conference in Barcelona from September 13-17. This fourth and final blog in our series of updates summarizes highlights from these discussions. 

You can read the other update blogs from these fall science meetings: 

Read time: 5 minutes.  

This is Part 3 in our series on how drugs get approved to treat lung cancer.  

Read time: 6 minutes. 

This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are important for new drug development. 

Read time: 3 minutes.

This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming weeks.

Have you ever wondered how a new medicine or drug to treat lung cancer is brought to the people who need it? That’s what clinical trials help us do.